Topics:
Thoracic Malignancies • Medical Oncology
In patients with driver mutation positive NSCLC who have progressed on targeted therapy and are planned for chemotherapy as the next line of treatment, for which driver alterations do you add in IO and which do you omit IO?
Taking into account multiple actionable mutations, where do you position IO in the sequence of treatments?